Sign In
Buy ITRM
$0.0300
+0 (+0%)
At Close: Jun 30, 2026
Iterum Down as Sulopenem Antibiotic Fails in Phase III Study
02:42pm, Thursday, 12'th Dec 2019
Iterum's antibiotic candidate, sulopenem, fails to meet the primary endpoint of non-inferiority to Merck's Invanz in a late-stage study, evaluating it in complicated intra-abdominal infections.
The Daily Biotech Pulse: Correvio Faces FDA Panel Rejection, Iterum's Antibiotic Trial Narrowly Misses Primary Endpoint
12:21pm, Wednesday, 11'th Dec 2019
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 10) Acceleron Pharma Inc (NASDAQ: XLRN ) Aimmune Thera
Iterum Therapeutics plc (ITRM), a clinical-stage pharmaceutical company focused on developing an oral and IV penem antibiotic to treat infections caused by multi-drug resistant pathogens in both commu
Is Iterum Therapeutics plc (ITRM) Going To Burn These Hedge Funds ?
03:18pm, Saturday, 30'th Nov 2019
Based on the fact that hedge funds have collectively under-performed the market for several years, it would be easy to assume that their stock picks simply aren't very good. However, our research show
Iterum Therapeutics plc (ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in bo
Iterum Therapeutics PLC (ITRM) Reports Q3 Loss, Lags Revenue Estimates
12:05am, Wednesday, 13'th Nov 2019
Iterum Therapeutics PLC (ITRM) delivered earnings and revenue surprises of -14.97% and -100.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for th
Iterum Therapeutics Reports Third Quarter 2019 Financial Results and Highlights
09:30pm, Tuesday, 12'th Nov 2019
--Phase 3 topline data from the cIAI trial expected shortly-- --cUTI and uUTI Phase 3 trials remain on track to complete enrollment around year-end and report topline data in.
